Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
UCSF baloxavir - renal and hemodialysis recommendations
Product / population
Adults weighing at least 40 kg with acute uncomplicated influenza; oral baloxavir tablets. Pediatric and liquid formulations are outside this summary.
University of California San Francisco (UCSF) · Adults weighing at least 40 kg with acute uncomplicated influenza; oral baloxavir tablets. Pediatric and liquid formulations are outside this summary.
Renal method: Weight-based dosing; qualitative renal/HD guidance Source date: Revision date not stated on the reviewed page. Retrieved: 2026-09-05
Separate professional-source protocol; not automatically equivalent to product labeling.
Source-specific renal protocol
UCSF recommends 40 mg orally once for uncomplicated influenza at 40-79 kg and 80 mg once for its printed >80 kg group. It states that neither renal impairment nor hemodialysis requires dose adjustment.
RDM31-baloxavir-prof-1 · Source locator: Adult and intermittent/continuous hemodialysis tables
Source-specific limits
The printed weight groups omit exact 80 kg and fractional weights above 79 but below 80. The U.S. label defines 40 to <80 and >=80 for this adult scope. The institutional renal recommendation goes beyond the label's severe-renal pharmacokinetic evidence.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.